Pancreatology MD

The Department of Molecular and Clinical Cancer Medicine is the centre for large European pancreas studies aimed at examining the benefit of chemotherapy and chemoradiotherapy in the treatment of patients who have undergone surgery to remove pancreas cancer tissue. The University has invested over £20million in cancer research which has been used for the creation of several new posts in the Department, and in the establishment of the University of Liverpool Cancer Research Centre (ULCRC) building.

Pancreatology is one of Liverpool’s recognised strengths with scientific expertise in Pancreatic cancer and pancreatitis and strong clinical and science leadership. Clinical trials aimed at determining the overall benefits of current treatments and evaluating the benefits of newly emerging treatments for pancreatic cancer. The Division of Surgery and Oncology is the centre for large European pancreas studies including the ESPAC clinical trials aimed at examining the benefit of chemotherapy and chemoradiotherapy (the combined use of chemotherapy and radiotherapy) in the treatment of patients who have undergone surgery to remove pancreas cancer tissue.

The Development and Co-ordination of the world's largest collection of families with Hereditary Pancreatitis and Familial Pancreas Cancer. Researchers in the department are currently working with these families to identify the underlying genetic cause of cancer in patients where the disease is inherited. In young patients with Hereditary Pancreatitis and Idiopathic Pancreatitis we are trialling novel treatments to inhibit or minimize the frequency or severity of the attacks.